Dr Octavio A Borges, MD in Newport, RI - Medicare Ophthalmology

Dr Octavio A Borges, MD is a medicare enrolled "Ophthalmology" physician in Newport, Rhode Island. His current practice location is 43 Smith Rd, Naval Health Care New England Newport, Newport, Rhode Island. You can reach out to his office (for appointments etc.) via phone at (860) 694-2377.

Dr Octavio A Borges is licensed to practice in Massachusetts (license number 159418) and he also participates in the medicare program. He does not accept medicare assignments directly but he may accept medicare through third-party (refer to Reassignment section below) and may also prescribe medicare part D drugs. His NPI Number is 1619949310.

Contact Information

	Dr Octavio A Borges, MD
	43 Smith Rd, Naval Health Care New England Newport, Newport, RI 02841-1002
	(860) 694-2377
	(860) 694-3590

Physician's Profile

Full Name	Dr Octavio A Borges
Gender	Male
Speciality	Ophthalmology
Location	43 Smith Rd, Newport, Rhode Island
Accepts Medicare Assignments	Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs.

NPI Data:

NPI Number: 1619949310
Provider Enumeration Date: 02/06/2006
Last Update Date: 07/08/2007

Medicare PECOS Information:

PECOS PAC ID: 6709067853
Enrollment ID: I20190523001485

Medical Identifiers

Medical identifiers for Dr Octavio A Borges such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1619949310	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207W00000X	Ophthalmology	159418 (Massachusetts)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Octavio A Borges is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Octavio A Borges, MD Route 12 Bldg 449, Attn Professional Affairs, Groton, CT 06349-5600 Ph: (860) 694-2377	Dr Octavio A Borges, MD 43 Smith Rd, Naval Health Care New England Newport, Newport, RI 02841-1002 Ph: (860) 694-2377

News Archive

Echo Therapeutics makes significant advance in designing Symphony tCGM device

Echo Therapeutics, Inc., a company developing the needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, announced today that the Company has made a significant advance in the product design of its Symphony tCGM device and that it has developed its next generation electronic component package.

Cholesterol drug Niaspan fails to protect heart: Study

According to researchers at the National Heart, Lung, and Blood Institute (NHLBI), increasing the dose of niacin to patients with heart disease who are already taking a cholesterol-lowering statin does nothing extra to prevent heart attacks and strokes. Approximately one out of seven Americans have high blood cholesterol, a main risk factor in heart disease, which kills some 800,000 people in the United States annually.

Understanding heart mutations that cause sudden cardiac arrest

New biosciences research at the University of Kent could point the way to greater understanding of the heart mutations that cause sudden cardiac arrest.

CRISPR-Cas9-based strategy allows researchers to precisely alter hundreds of different genes

Geneticists have been using model organisms ranging from the house mouse to the single-cell bakers' yeast, Saccharomyces cerevisiae, to study basic biological processes that regulate human development and physiology, and that can be compromised in various diseases.

pSivida reports that NICE issues draft guidance for use of ILUVIEN for pseudophakic patients with DME

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that the United Kingdom's National Institute for Health and Care Excellence issued draft guidance recommending ILUVIEN for the treatment of pseudophakic patients (those who have undergone prior cataract surgery) with chronic diabetic macular edema considered insufficiently responsive to available therapies.

Dr Octavio A Borges, MD - Medicare Ophthalmology in Newport, RI